Whitehawk Raises Liquidity to $169.7 Million, Expects to Fund Operations Through 2028

Key Facts

Whitehawk Therapeutics said cash, cash equivalents and short-term investments totaled $169.7 million on September 30, 2026, compared with $145.7 million on December 31, 2025, and said the balance was sufficient to fund operations through the second half of 2028 under its current plans. That estimate gives the company a funding runway extending beyond clinical data readouts it expects next year. The announcement came with third-quarter results that also showed wider losses and higher research and development expenses than in the same period a year earlier. The company also said it had begun a Phase 1 trial of HWK-206 in the United States and that the drug had received Fast Track designation from the U.S. Food and Drug Administration. WHWK closed at $3.13 in the November 6 session, according to EL7 data.

Net loss was $21.2 million in the third quarter of 2026, compared with $17.7 million in the third quarter of 2025. Research and development expenses rose to $18.1 million from $14.3 million in the same period a year earlier. These figures put drug-development spending in the context of the liquidity the company reported, as Whitehawk funds its clinical programs while posting larger quarterly losses. The company’s current plans put its funding runway through the second half of 2028, while it is targeting clinical data readouts during 2027. The company did not indicate in the statements cited here that it had changed the funding runway tied to those plans.

On the trial front, Chief Executive Dave Lennon said the company continued dose escalation in the Phase 1 studies of HWK-007 and HWK-016 and remained on track to announce preliminary data in the first half of 2027. He added: "We continue to dose escalate patients... and remain on track to announce preliminary data in the first half of 2027." Lennon also said the company had begun a Phase 1 trial of HWK-206. The company thus distinguishes between the expected first-half 2027 data readouts from the two ongoing programs and preliminary data from HWK-206, expected by the end of the same year. This distinction allows the company’s programs to be tracked against separate announced timelines rather than treating portfolio readouts as a single event.

Whitehawk began a Phase 1 trial of HWK-206 in the United States, and the drug received Fast Track designation from the U.S. Food and Drug Administration. The company is initially developing the drug to treat small cell lung cancer and other neuroendocrine tumors. The designation points to an expedited regulatory pathway, but does not mean the treatment has been approved. The company expects to announce preliminary Phase 1 data by the end of 2027. It also aims to activate its first clinical sites in China during the first quarter of 2027, after submitting an investigational new drug application there. These steps place the start of the U.S. trial within a development plan that includes expected clinical expansion in China, with the activation and data timelines remaining the milestones the company has announced for tracking.

The company’s upcoming milestones also include two management appearances at healthcare conferences. Chief Executive Dave Lennon will participate in a fireside chat at the Jefferies Healthcare Conference in London on November 16, 2026, at 9:30 a.m. GMT. Management will also present the company at the Piper Sandler Healthcare Conference on December 2, 2026, at 1:30 p.m. Eastern Time. These dates follow the third-quarter results and precede the preliminary data readouts expected from the HWK-007 and HWK-016 studies in the first half of 2027. The company expects preliminary HWK-206 data by the end of 2027, while targeting activation of clinical sites in China in the first quarter of that year.